Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) Syndrome

ARC syndrome is a very rare, inherited? condition that affects many organs from birth. Babies are usually born with arthrogryposis (stiff joints that do not move fully), develop kidney problems (especially loss of salts, sugars, and minerals in the urine due to renal tubular dysfunction), and have liver problems called cholestasis (poor bile flow causing jaundice?). In ARC, the bile blockage usually happens without a rise in GGT (a liver enzyme), so doctors often call it “low-GGT cholestasis.” The condition is caused by changes (variants) in one of two genes, VPS33B or VIPAS39/VIPAR, which work together to help cells sort and deliver proteins to the correct side of the cell. When these genes do not work, cells in the liver, kidney, skin, and other tissues lose their normal “polarity,” so transporters and channels end up in the wrong place. This explains the combination of jaundice, kidney salt wasting, dry scaly skin (ichthyosis), bleeding tendency from abnormal platelets, and other features seen in ARC. Most children show symptoms in the newborn period?; classic ARC can be life-limiting, though milder forms and longer survival are reported. BioMed Central+2Rare Diseases +2

Another names

Doctors and references may use several names for this condition:

• Arthrogryposis-renal dysfunction-cholestasis syndrome (ARC)

• ARC syndrome type 1 (ARCS1) when changes are in VPS33B

• ARC syndrome type 2 (ARCS2) when changes are in VIPAS39/VIPAR

• VPS33B-related disorder or VIPAS39-related disorder

• Low-GGT cholestasis with renal tubular dysfunction and arthrogryposis
  These names all refer to the same overall disease spectrum caused by defects in the VPS33B–VIPAR protein-sorting pathway. BioMed Central+1

Types

Two molecular types are recognized based on which gene is altered:

1. ARCS1 (VPS33B-related): The more common form worldwide. It ranges from classic, severe? infant disease to milder phenotypes with survival into later childhood in some reports. BioMed Central+1

2. ARCS2 (VIPAS39/VIPAR-related): Clinically overlaps with ARCS1. Some patients show variable severity and can be under-diagnosed if not all “classic” features are present. PubMed

Both types disturb vesicle-mediated protein sorting and apical-basolateral polarity in epithelial cells (liver, kidney, skin) and can cause platelet α-granule deficiency that increases bleeding risk. ASH Publications+1

Causes

Although ARC is a genetic disease with two core gene causes, doctors describe multiple mechanistic “causes” or pathways that together produce the full syndrome. Each item below explains a real contributor to the disease picture.

1. Biallelic VPS33B variants: Both copies of VPS33B are altered, breaking a key trafficking protein and producing ARCS1. BioMed Central

2. Biallelic VIPAS39 (VIPAR) variants: Both copies of VIPAS39 are altered, disrupting the VPS33B partner protein and producing ARCS2. BioMed Central

3. Loss of epithelial cell polarity: Transporters that should face the bile canaliculus or tubular lumen are mis-placed, blocking bile flow and wasting salts in urine. BioMed Central

4. Defective vesicle docking and fusion: Cargo vesicles cannot deliver proteins to the right membrane, harming liver and kidney function. ScienceDirect

5. Mislocalization of bile transporters: Bile salt pumps fail to reach canalicular membranes, causing low-GGT cholestasis and jaundice. BioMed Central

6. Renal tubular transporter mis-targeting: Sodium, phosphate, glucose, and bicarbonate transporters are not where they belong, leading to Fanconi-like losses. BioMed Central

7. Platelet α-granule biogenesis failure: Platelets lack α-granules and their contents, increasing bleeding and bruising?. ASH Publications+1

8. Keratinocyte polarity defects: Skin barrier is dry and scaly (ichthyosis) because lipid-processing and transport in skin cells are abnormal. BioMed Central

9. Neurodevelopmental impact: Polarity and trafficking problems can affect brain development, contributing to hypotonia and delays. BioMed Central

10. Bile acid retention and toxicity: Poor bile flow leaves bile acids in the liver, damaging cells and worsening jaundice. BioMed Central

11. Electrolyte depletion: Kidney losses of sodium, potassium, and bicarbonate cause dehydration?, acidosis, and poor growth. BioMed Central

12. Fat-soluble vitamin malabsorption?: Low bile in the intestine reduces absorption of vitamins A, D, E, K, leading to bone and bleeding issues. BioMed Central

13. Malnutrition/failure to thrive?: Reduced nutrient absorption plus high losses cause poor weight gain. BioMed Central

14. Founder or recurrent? variants in certain regions: Some populations report more cases due to shared variants. BioMed Central

15. Nonsense/frameshift variants producing truncated proteins: Often linked to severe, early presentations. Wiley Online Library

16. Missense variants with partial function: Sometimes linked to milder or longer-surviving phenotypes. PMC+1

17. Splice-site defects: Abnormal RNA splicing yields dysfunctional proteins and classic ARC features. Wiley Online Library

18. Secondary bone fragility: Vitamin D deficiency and poor nutrition lead to fractures or rickets-like changes. BioMed Central

19. Recurrent infections: Skin barrier problems, poor nutrition, and bleeding issues increase infection? risk. BioMed Central

20. Bleeding tendency: Platelet storage pool deficiency raises risk during procedures or when sick. ASH Publications

Symptoms

1. Stiff joints at birth (arthrogryposis): Joints do not move normally, especially hips, knees, and elbows. This is due to reduced movement in the womb? and nerve/muscle involvement. BioMed Central

2. Jaundice: Yellow eyes/skin from bile build-up because bile cannot flow well from the liver. BioMed Central

3. Pale or clay-colored stools and dark urine: Little or no bile reaches the gut, so stools lose color. BioMed Central

4. Intense itching? (pruritus?): Bile acids in the blood irritate the skin and nerves. BioMed Central

5. Poor weight gain (failure to thrive): Children cannot absorb enough fats and vitamins and also lose salts in urine. BioMed Central

6. Frequent urination? and thirst: Kidneys lose salt, bicarbonate, glucose, and phosphate, pulling water with them. BioMed Central

7. Dehydration and metabolic acidosis: Loss of fluids and bicarbonate causes fast breathing and sleepiness in babies. BioMed Central

8. Easy bruising or bleeding: Platelets lack α-granules and do not work properly. ASH Publications

9. Dry, scaly skin (ichthyosis): The skin barrier is poor because of abnormal cell polarity and lipid handling. BioMed Central

10. Muscle weakness? or low tone (hypotonia): Nerve and muscle function may be affected, leading to delayed motor milestones. BioMed Central

11. Bone fragility or rickets-like changes: Vitamin D and calcium losses weaken bones. BioMed Central

12. Infections: Cracked skin, poor nutrition, and repeated hospital care can raise infection risk. BioMed Central

13. Vomiting? or feeding problems: Liver disease and electrolyte shifts can reduce appetite and tolerance of feeds. BioMed Central

14. Developmental delay: Ongoing illness, nutrition issues, and neurologic involvement may slow development. BioMed Central

15. Hearing or vision problems (in some): Some reports include sensorineural issues or structural anomalies. BioMed Central

Diagnostic tests

ARC is diagnosed by combining clinical? features with laboratory, imaging, and especially genetic testing.

Physical examination

1. Newborn joint exam: The clinician looks for contractures and reduced range of motion in several joints, a hallmark of arthrogryposis. BioMed Central

2. Skin inspection: Dry, scaly skin (ichthyosis), bruises, or bleeds suggest ARC and its platelet problem. BioMed Central+1

3. Growth and nutrition assessment?: Weight, length, and head size are checked for poor growth due to malabsorption and kidney losses. BioMed Central

4. Hydration status: Dry mouth, sunken fontanelle?, or low tears point to salt and water losses from renal tubular dysfunction. BioMed Central

5. Neurologic and tone exam: Low tone or delayed primitive reflexes can appear in ARC and guide supportive therapy. BioMed Central

Manual/bedside tests

6. Range-of-motion testing: Gentle movement of each joint maps the severity and guides splinting/physiotherapy. BioMed Central

7. Ortolani/Barlow hip maneuvers: These screen for hip instability/dislocation?, common in arthrogryposis. BioMed Central

8. Stool color check: Pale stools support cholestasis; this simple check is helpful in newborn jaundice clinics. BioMed Central

9. Pruritus assessment scales: Simple caregiver-reported itch scoring can track cholestasis severity and response. BioMed Central

Laboratory and pathological tests

10. Liver panel with GGT: Bilirubin (direct), ALT/AST, alkaline phosphatase, and GGT are measured. Low/normal GGT with cholestasis is a red flag for ARC. WJGnet

11. Serum bile acids: High serum bile acids support poor bile flow when GGT is not elevated. BioMed Central

12. Electrolytes and acid-base profile: Low sodium/potassium and metabolic acidosis reflect renal tubular dysfunction. BioMed Central

13. Urinalysis with losses: Urine shows glucosuria, phosphaturia, aminoaciduria—a Fanconi-like picture typical of ARC kidneys. BioMed Central

14. Fat-soluble vitamins (A, D, E, K) and coagulation tests: Low vitamin levels and prolonged PT/INR suggest malabsorption and risk of bleeding. BioMed Central

15. Platelet studies (light/EM if available): Platelets often show absent α-granules (“gray” platelets) and functional defects. ASH Publications+1

16. Liver biopsy (selected cases): Can show cholestasis and mislocalization of canalicular proteins; today often avoided if genetic proof is available. BioMed Central

Electrodiagnostic tests

17. Nerve conduction studies/EMG: If low tone or weakness is unexplained, these tests assess peripheral nerve/muscle function and can document neurogenic features sometimes reported in ARC. BioMed Central

18. Auditory brainstem response (ABR): Screens for sensorineural hearing issues that can accompany multisystem disease and affect development. BioMed Central

Imaging tests

19. Renal ultrasound: Looks for kidney size and structure, but in ARC the main problem is tubular function; still useful to exclude other causes. BioMed Central

20. Abdominal ultrasound/Elastography: Evaluates liver size and bile ducts; in ARC, ducts are usually not obstructed, helping distinguish from surgical causes of jaundice. BioMed Central

Non-pharmacological treatments (therapies & other supports)

1) Family-centered care plan
A written, shared plan lists all problems (jaundice, kidney losses, skin, nutrition, bleeding risk). It sets clinic schedules (liver, kidney, nutrition, physio), lab monitoring (electrolytes, acid–base, vitamins A/D/E/K), and safety steps (bleeding precautions). Purpose: coordinate complex care and catch problems early. Mechanism: early detection plus timely response reduces hospital visits and prevents severe complications like dehydration, fractures, or bleeding. Multisystem checklists are recommended in rare multi-organ diseases like ARC. Orpha+1

2) Feeding support with high-energy nutrition
Babies with cholestasis absorb fat poorly. Dietitians often use breast milk plus added calories or specialized formulas with medium-chain triglycerides (MCT), which are absorbed without bile. Purpose: help weight gain and growth. Mechanism: MCTs enter cells directly and improve energy intake when long-chain fats are not absorbed. Most guidance supports MCT-enriched feeds and careful adjustment so essential fatty acids are not lacking. NASPGHAN+2PMC+2

3) Fat-soluble vitamin program (A, D, E, K) monitoring
Cholestasis blocks bile-dependent vitamin absorption. Teams check vitamin levels regularly and give water-miscible forms. Purpose: prevent bleeding (vit K), rickets/fractures (vit D), vision issues (vit A), and nerve/muscle problems (vit E). Mechanism: proactive lab-guided dosing replaces what is not absorbed and avoids toxicity. PMC+2Binasss+2

4) Pruritus (itch) skincare and routines
Itch is common in cholestasis. Non-drug steps include short tepid baths, emollients for ichthyosis, soft clothing, trimmed nails, and sleep routines. Purpose: reduce scratching and skin breaks that can get infected. Mechanism: skin barrier care lowers irritation while drug therapy for cholestasis is optimized. AASLD

5) Oral rehydration and electrolyte replacement plan
Kidney tubules in ARC often lose bicarbonate, sodium, potassium, and phosphate. Families get clear fluid plans for fever, vomiting, or hot weather; clinics provide written “sick day” instructions. Purpose: prevent dehydration and metabolic acidosis. Mechanism: timely fluids and electrolytes replace ongoing renal losses common in Fanconi-like states. NCBI+1

6) Physiotherapy for contractures
Gentle range-of-motion, splinting, and positioning start early. Purpose: prevent worsening joint stiffness and support comfort and function (feeding, holding). Mechanism: low-load stretch and frequent repositioning keep soft tissues flexible and may improve daily care tasks. (Contractures are a core feature of ARC.) Orpha

7) Occupational therapy for feeding and handling
OT teaches caregivers positions and tools (special bottles, seats) that protect stiff joints and reduce stress during feeds. Purpose: safer feeding and better energy intake. Mechanism: ergonomic support reduces effort and improves coordination with physiotherapy. Orpha

8) Bleeding precautions education
Because ARC platelets lack α-granules, bleeding can be serious, especially after procedures. Families learn to avoid trauma, use soft toothbrushes, and alert teams before any surgery or biopsy. Purpose: lower bleeding risk. Mechanism: prevention plus rapid access to hospital care for significant bleeds. ASH Publications+1

9) Infection prevention bundle
Hand hygiene, avoiding sick contacts, routine vaccines (per schedule), and RSV season protection (see drugs section for antibody options). Purpose: reduce infections, which can trigger dehydration and sepsis. Mechanism: layered prevention lowers exposure and boosts passive protection in high-risk seasons. Rare Diseases

10) Skin care for ichthyosis
Daily emollients, humidified rooms, and careful bathing help the dry, scaly skin seen in ARC. Purpose: improve comfort and reduce skin breaks. Mechanism: restoring moisture helps the barrier while general cholestasis care proceeds. BioMed Central

11) Bone health support
With vitamin D deficiency and acidosis, bones are fragile. Care plans include vitamin D repletion, adequate calcium/phosphate, and control of acidosis (see drugs). Purpose: prevent rickets and fractures. Mechanism: replacing vitamins and correcting acidosis improves bone mineralization. PMC+1

12) Genetic counseling
ARC is autosomal recessive. Families benefit from counseling on recurrence risk and options in future pregnancies. Purpose: informed family planning. Mechanism: DNA results (VPS33B or VIPAS39) guide risk estimates. Nature+1

13) Early palliative and symptom care
A palliative team can help with comfort, sleep, itch, feeding stress, and family goals even while all medical care continues. Purpose: improve quality of life. Mechanism: proactive relief of symptoms and support for decisions in a complex rare disease. Rare Diseases

14) Multidisciplinary follow-up
Regular visits with hepatology, nephrology, nutrition, hematology, dermatology, PT/OT, and genetics are standard in ARC. Purpose: keep many moving parts aligned. Mechanism: scheduled labs and dose changes maintain stability. Orpha

15) Safe procedure planning
If a biopsy or surgery is necessary, teams plan hemostasis support and post-op monitoring because of platelet granule defects. Purpose: reduce bleeding complications. Mechanism: anticipatory platelet/antifibrinolytic support and careful technique. ASH Publications+1

16) Temperature and hydration vigilance
Polyuria from tubular dysfunction makes dehydration easier during fevers/heat. Families are taught early signs and have a low threshold to seek care. Purpose: prevent shock and kidney injury. Mechanism: rapid fluid replacement addresses renal salt/bicarbonate losses. Medscape

17) Developmental stimulation
Gentle play, music, and interaction within the child’s comfort help neurodevelopment while minimizing fatigue from illness. Purpose: support learning and bonding. Mechanism: structured sensory and motor input within safe limits. Rare Diseases

18) Caregiver training for medication timing
Some cholestasis medicines must be timed away from other drugs or feeds (e.g., cholestyramine can bind other meds). Purpose: improve drug effect. Mechanism: spacing doses as per guidance (see drugs) avoids interactions. MDPI

19) Written emergency plan
Families carry a one-page summary (diagnosis, bleeding risk, usual meds/doses, contacts) for ER visits. Purpose: speed safe care in unfamiliar hospitals. Mechanism: reduces delays in giving alkali, vitamins, or hemostatic support. Rare Diseases

20) Community resources and rare-disease support
Connecting with rare-disease groups can reduce isolation and improve adherence. Purpose: peer support and practical tips. Mechanism: shared experience and vetted education improve daily care. Rare Diseases

Drug treatments

For each item: long description (~150 words), class, usual pediatric dose/time (typical ranges), purpose, mechanism, and key side effects. Doses must be individualized by the child’s clinicians.

1) Ursodeoxycholic acid (UDCA)
Class: bile acid. Dose: commonly 10–30 mg/kg/day in 2–3 doses (clinician-adjusted). Purpose: improve bile flow, stooling, and sometimes itch in cholestasis. Mechanism: UDCA replaces toxic bile acids with a more hydrophilic bile acid, improves cholangiocyte protection, and can increase bile flow in some genetic cholestasis states. Side effects: diarrhea, rarely worsening pruritus or elevated LFTs; benefit varies by cause, and lack of response should prompt reevaluation. Evidence supports UDCA across pediatric cholestasis as symptomatic therapy; it does not cure ARC. NCBI+1

2) Cholestyramine
Class: bile acid sequestrant. Dose: 4 g up to 4×/day; give ≥20 min before meals and ≥4 h apart from other medicines. Purpose: reduce pruritus by binding bile acids in the gut. Mechanism: resin traps bile acids; stool carries them out, lowering circulating bile acids that drive itch. Side effects: constipation, bloating, poor taste; can bind fat-soluble vitamins and other drugs, so timing and vitamin monitoring are essential. AASLD+1

3) Rifampin (Rifampicin)
Class: enzyme inducer antibiotic used off-label for cholestatic pruritus. Dose: often 5–10 mg/kg/day (clinician-adjusted). Purpose: second-line itch control when cholestyramine/UDCA are not enough. Mechanism: induces hepatic enzymes and transporters, lowering pruritogens like bile acids or autotaxin-related mediators. Side effects: drug interactions, hepatitis, orange secretions; monitor LFTs. Pediatric cholestasis and PFIC guidance support rifampin trials for pruritus. PMC+1

4) Naltrexone
Class: opioid receptor antagonist. Dose: specialist-guided; titration is required. Purpose: third-line option for itch. Mechanism: blocks endogenous opioids that may mediate cholestatic pruritus. Side effects: abdominal pain, insomnia; avoid if risk of acute withdrawal in opioid-exposed patients. Used in stepwise cholestatic itch algorithms. AASLD

5) Sertraline
Class: SSRI. Dose: clinician-determined low-dose start. Purpose: adjunct for refractory itch. Mechanism: central modulation of itch pathways. Side effects: GI upset, sleep change; drug interactions must be reviewed. Included as later-line in hepatology itch pathways. AASLD

6) Vitamin K (phytonadione)
Class: fat-soluble vitamin. Dose: individualized; often higher and water-miscible forms in cholestasis. Purpose: prevent and treat bleeding due to malabsorption. Mechanism: restores γ-carboxylation of clotting factors. Side effects: rare anaphylactoid reactions with IV form; monitor PT/INR. Programs recommend routine supplementation and monitoring in cholestatic infants. PMC+1

7) Vitamin D (cholecalciferol/ergocalciferol or calcifediol)
Class: fat-soluble vitamin. Dose: repletion often 1000–10 000 IU/day for 8–12 weeks then maintenance, tailored to levels; water-miscible forms help absorption. Purpose: prevent/treat rickets and fractures. Mechanism: improves calcium/phosphate handling and bone mineralization. Side effects: hypercalcemia if overdosed; monitor levels and adjust. Pediatr Neonatol+1

8) Vitamin A
Class: fat-soluble vitamin. Dose: individualized (e.g., 3000–10 000 IU/day in some neonatal cholestasis protocols) with level monitoring. Purpose: prevent eye and skin complications. Mechanism: restores retinoid-dependent tissue function. Side effects: toxicity with over-supplementation (bone, liver); careful lab tracking required. ANMF Formulary+1

9) Vitamin E (tocopherol/tocofersolan)
Class: fat-soluble vitamin (often water-soluble preparations). Dose: individualized to levels. Purpose: prevent neurologic and muscle problems in deficiency. Mechanism: antioxidant function in membranes. Side effects: bruising risk at high doses; monitor. Regular checks are advised because deficiency is common in cholestatic infants. PMC

10) Sodium bicarbonate or potassium citrate (alkali therapy)
Class: systemic alkali. Dose: varies by RTA type; proximal RTA often needs large doses (e.g., up to ~10–20 mEq/kg/day in divided doses); distal RTA often lower (e.g., ~4–6 mEq/kg/day in infants). Purpose: correct metabolic acidosis due to renal tubular losses. Mechanism: replaces lost bicarbonate, protecting bone and growth. Side effects: gastric upset; citrate options add potassium (watch potassium level). Pediatric RTA/Fanconi guidance supports aggressive alkali in infants. IJPediatrics+2IAP KPJ+2

11) Phosphate supplements and active vitamin D (if needed)
Class: minerals/hormone. Dose: clinician-guided based on labs. Purpose: correct hypophosphatemia from tubular losses and support bone. Mechanism: restores serum phosphate; calcitriol may be used if needed for mineral metabolism. Side effects: GI upset; monitor calcium/phosphate to avoid nephrocalcinosis. Renaissance School of Medicine

12) Potassium supplements
Class: electrolyte. Dose: individualized (often 1–2 mEq/kg/day additions). Purpose: treat hypokalemia from renal losses or diuretics used with alkali therapy. Mechanism: replaces urinary losses. Side effects: GI irritation, arrhythmia risk if overdosed; close monitoring needed. IAP KPJ

13) Hydrochlorothiazide (selected cases)
Class: thiazide diuretic. Dose: e.g., 1–3 mg/kg/day when used to help retain bicarbonate in proximal RTA under nephrology guidance. Purpose: paradoxically reduce bicarbonate loss by mild volume contraction, enabling lower alkali doses. Mechanism: increases proximal reabsorption threshold. Side effects: worsens potassium loss; needs potassium supplementation. Medscape

14) Antifibrinolytics (e.g., ε-aminocaproic acid or tranexamic acid)
Class: antifibrinolytic agents. Dose: specialist-guided. Purpose: reduce mucosal or post-procedural bleeding in platelet granule defects. Mechanism: block fibrin clot breakdown. Side effects: thrombosis risk is low but monitor; avoid in gross hematuria. Case reports in ARC describe benefit. PMC

15) Platelet transfusion (procedure-related or major bleeding)
Class: blood product. Dose: per hematology protocols. Purpose: temporary hemostasis support when bleeding risk is high (e.g., surgery). Mechanism: provides functional platelets with α-granules. Side effects: transfusion reactions; use judiciously. Bleeding after biopsies and major hemorrhage are reported in ARC, so planning is key. ASH Publications

16) Broad-spectrum antibiotics (when infection suspected)
Class: antimicrobials. Dose: per sepsis protocols. Purpose: treat or prevent rapid deterioration from infections in high-risk infants. Mechanism: early coverage for common neonatal pathogens. Case series show infections are a frequent cause of decline in ARC. ResearchGate

17) Pruritus adjuncts (phenobarbital is generally avoided/limited)
Class: enzyme inducer sedative (historical use). Dose: not first-line due to sedation and limited benefit; may be tried by specialists when other options fail. Purpose: itch relief. Mechanism: enzyme induction; but modern guidelines favor other agents first. Side effects: sedation, dependence, drug interactions. AASLD

18) MCT oil additions (technically a medical food, but used like a “therapy”)
Class: nutrition support. Dose: % of total fat often targeted to ~30–50% MCT under dietitian care to avoid essential fatty acid deficiency. Purpose: improve caloric absorption. Mechanism: passive intestinal absorption without bile micelles. Side effects: diarrhea; ensure essential fatty acids are provided. BioMed Central+1

19) Topical emollients/urea-based creams
Class: dermatologic moisturizers/keratolytics. Dose: daily to multiple times daily. Purpose: relieve ichthyosis discomfort and prevent fissures. Mechanism: repairs barrier and reduces transepidermal water loss. Side effects: irritation with some products; choose gentle options in infants. BioMed Central

20) RSV season antibody prevention (see below for details: nirsevimab/palivizumab)
Class: long-acting monoclonal antibodies. Dose: age/weight-based, once per season (nirsevimab) or monthly (palivizumab) per AAP/CDC guidance. Purpose: reduce severe RSV infections in fragile infants with chronic disease. Mechanism: passive neutralizing antibodies. Side effects: usually mild; follow eligibility rules and availability. CDC+1

Dietary molecular supplements

Each includes long description (~150 words), typical dosing concepts, function, and mechanism; always clinician-guided.

1) Water-miscible multivitamin base
Daily multivitamins in water-soluble forms improve absorption in cholestasis. They do not replace the need for separate high-dose A/D/E/K, but they help cover other vitamins and trace elements while weight and labs are monitored. Dose: product-specific per weight; clinician adjusts. Function: broad micronutrient coverage. Mechanism: avoids fat-based carriers that are poorly absorbed when bile is low. Monitor labs to prevent deficiency or excess. PMC

2) Vitamin A (retinol) as a separate supplement
Often needed beyond multivitamins. Dose: individualized (e.g., 3,000–10,000 IU/day ranges appear in neonatal cholestasis protocols), with level monitoring. Function: vision and epithelial health. Mechanism: restores retinoid pathways reduced by fat malabsorption. Safety: avoid overdose; frequent checks recommended. ANMF Formulary+1

3) Vitamin D (cholecalciferol/calcifediol)
Dose: high-dose repletion then maintenance (e.g., 1,000–10,000 IU/day for 8–12 weeks when deficient, then adjusted). Function: bone mineralization and immune support. Mechanism: improves calcium/phosphate handling impaired by cholestasis and acidosis. Safety: monitor calcium and 25-OH-D. Pediatr Neonatol

4) Vitamin E (often as tocofersolan)
Dose: level-guided. Function: antioxidant protection for nerves and muscles. Mechanism: water-soluble forms bypass bile-dependent absorption. Safety: monitor due to bleeding risk at high levels. PMC

5) Vitamin K (phytonadione)
Dose: individualized and sometimes parenteral if severe deficiency. Function: normal clotting. Mechanism: restores vitamin-K–dependent factors depleted by malabsorption. Safety: monitor PT/INR; avoid IV bolus except when necessary. PMC

6) Medium-chain triglyceride (MCT) oil or MCT-enriched formula
Dose: dietitian sets % of total fat (often ~30–50%); balance with essential long-chain fats. Function: increase calories and fat absorption. Mechanism: MCTs absorb without bile. Safety: watch stools, weight, and essential fatty acid status. NASPGHAN+1

7) Calcium and phosphate
Dose: lab-guided; may need both, plus active vitamin D, if bone disease risk is high. Function: support bone mineralization. Mechanism: replaces renal losses and works with vitamin D to build bone. Safety: monitor urine calcium to avoid nephrocalcinosis. Renaissance School of Medicine

8) Zinc
Dose: dietitian-guided if deficiency. Function: growth and skin health; may help with diarrhea. Mechanism: replenishes losses due to malabsorption. Safety: excess can lower copper; monitor levels. NASPGHAN

9) Essential fatty acids (linoleic/alpha-linolenic; sometimes DHA/ARA)
Dose: ensure adequate long-chain fats in addition to MCTs. Function: neurodevelopment, skin, and retina. Mechanism: corrects potential deficiency when MCT proportion is high. Safety: balance calories to avoid GI upset. ResearchGate

10) Iron (when iron-deficiency anemia is confirmed)
Dose: per pediatric guidelines. Function: treat anemia from poor intake or blood loss. Mechanism: provides iron for hemoglobin. Safety: constipation, dark stools; avoid if ferritin high. NASPGHAN

Medicines for immune prevention / regenerative ideas

ARC has no proven disease-modifying or stem-cell drug today. The items below are realistic, evidence-based prevention measures for fragile infants.

1) Nirsevimab (long-acting RSV monoclonal antibody)
Dose: single weight-based injection once per RSV season (AAP/CDC schedules). Function: reduce severe RSV infections and hospitalizations. Mechanism: passive neutralizing antibodies for about 5 months. Strong population data and guidance support use in eligible infants. CDC+2CDC+2

2) Palivizumab (RSV monoclonal for selected high-risk infants)
Dose: 15 mg/kg IM monthly, up to 5 doses per season, when indicated. Function: RSV prevention in infants at defined high risk or when nirsevimab is not available. Mechanism: passive antibodies; shorter-acting than nirsevimab. Notes: Follow AAP criteria. Hopkins Guides+1

3) Routine immunizations per schedule (including maternal RSV or infant RSV antibodies as appropriate)
Dose: national program schedule. Function: prevent vaccine-preventable infections that can destabilize ARC. Mechanism: active immunity (vaccines) and/or passive immunity (monoclonals) based on age/season. CDC

4) Aggressive vitamin repletion to “regenerate” bone health
Dose: as above for D/A/E/K with minerals and alkali. Function: rebuild bone and reduce fractures. Mechanism: corrects deficiency and acidosis, enabling normal bone formation. (No true “stem cell” drug exists for ARC at this time.) PMC+1

5) Thoughtful consideration of liver transplantation (selected, atypical/milder cases)
Dose: surgical therapy, not a drug. Function: may help severe liver disease in rare cases; outcomes vary because extra-hepatic problems persist. Mechanism: replaces diseased liver but not kidney/platelet defects. Case reports show survival in selected patients; decision is highly individualized. Journal of Pediatric Research

6) Clinical trials / natural history registries (future therapies)
Function: access to emerging treatments and structured follow-up. Mechanism: research improves understanding of VPS33B/VIPAS39 biology and care pathways. Families can discuss research options with genetics centers. PubMed

Surgeries

1) Central line placement or gastrostomy (G-tube) when needed
Procedures to secure IV access for difficult admissions or to support long-term feeding if oral intake fails. Why: improve nutrition, hydration, and medication delivery in complex ARC care. Risks include infection and bleeding, so planning is essential. Rare Diseases

2) Orthopedic soft-tissue releases or serial casting (selected joints)
For severe, function-limiting contractures, orthopedic teams may offer minor procedures or casting. Why: improve positioning, skin care, and comfort; sometimes aids feeding/handling. Bleeding precautions apply. Orpha

3) Biliary diversion (rare, selected cases with intractable itch)
In PFIC, partial external biliary diversion can reduce pruritus; in ARC, its role is uncertain and rarely used because disease is multisystemic. Why: possible itch relief when medical therapy fails. Note: a hepatology team must weigh risks/benefits carefully. BioMed Central

4) Liver transplantation (very selective)
Can help end-stage liver disease, but kidney and platelet defects remain. Why: considered only in carefully selected patients with supportive evidence and center experience. Individual case reports show longer survival; many cases are not candidates. Journal of Pediatric Research

5) Dental and minor surgical procedures with hemostasis plan
Dental extractions or other minor procedures may be needed and should be done with hematology support (antifibrinolytics ± platelets). Why: reduce bleeding complications in α-granule platelet defects. PMC

Preventions

1. Keep vaccine schedule (plus RSV prevention as eligible). Vaccines and RSV antibodies prevent serious infections that can trigger dehydration and sepsis. CDC

2. Daily vitamin program with lab checks. Prevents bleeding, rickets, and nerve/muscle problems. PMC

3. Dietitian visits and MCT-guided feeding. Supports growth despite poor fat absorption. NASPGHAN

4. Written fever and diarrhea plan. Early fluids and electrolytes prevent hospitalization. Medscape

5. Protect against bleeds. Avoid rough play and alert doctors before procedures. ASH Publications

6. Skin moisture routine. Daily emollients and gentle baths reduce skin breaks and infections. BioMed Central

7. Regular labs. Watch electrolytes, acid–base, vitamins A/D/E/K, liver tests, and growth markers. PMC

8. Physio/OT exercises at home. Gentle stretching and positioning maintain function. Orpha

9. Prompt infection treatment. Low threshold for care if fever, poor feeding, or lethargy. ResearchGate

10. Genetic counseling for family planning. Understand risks for future pregnancies. Nature

When to see a doctor (red flags)

See a doctor urgently for: fever, poor feeding, vomiting, fewer wet diapers, deep jaundice, very pale stools, unusual sleepiness, new bleeding or big bruises, fast breathing, or severe itch with skin breaks. These can signal dehydration, sepsis, worsening cholestasis, or bleeding. Early treatment is vital in ARC. Rare Diseases

What to eat and what to avoid

What to eat: breast milk if possible (often with added calories), or MCT-enriched formula as directed; adequate protein for growth; foods with essential fatty acids when age-appropriate; vitamin-rich feeds with water-miscible supplements as prescribed. Why: replaces energy and nutrients not absorbed well in cholestasis. NASPGHAN

What to avoid or limit: unnecessary fasting; very high MCT without essential long-chain fats (risk of deficiency); unapproved herbal products or “liver cleanses”; giving cholestyramine close to other meds or vitamins (it blocks absorption); high-impact activities with bleeding risk without medical advice. Why: safety and absorption. ResearchGate+1

Frequently asked questions

1) Is there a cure for ARC?
No cure exists yet. Care is supportive: manage cholestasis, kidney losses, nutrition, skin, bones, and bleeding risk. Research is ongoing. PMC

2) Which genes cause ARC?
VPS33B (ARCS1) and VIPAS39/VIPAR (ARCS2). Both affect protein trafficking and cell polarity. Nature+1

3) Why is my child’s GGT low but jaundice high?
ARC causes low-GGT cholestasis, meaning bile ducts are not inflamed but bile flow is poor due to cell transport defects. Genetic Rare Disease Center

4) Why are bones fragile?
Two reasons: vitamin D deficiency from malabsorption and chronic acidosis from kidney tubule loss. Both weaken bone unless treated. PMC+1

5) Why is bleeding a risk if platelet counts are “normal”?
ARC platelets often lack α-granules, so clotting signals are weak. Plan procedures carefully and consider antifibrinolytics/platelets when needed. Wiley Online Library

6) Do all children with ARC have severe disease?
No. Some have milder forms and live longer, but close monitoring is still needed. PMC+1

7) Can liver transplant fix ARC?
It may help selected patients with severe liver failure, but kidney and platelet problems remain, so benefits vary. Journal of Pediatric Research

8) Which medicines help itching most?
Start with cholestyramine and UDCA; add rifampin if needed; consider naltrexone or sertraline later. Doses and timing are specialist-guided. AASLD+1

9) How often should vitamins be checked?
Regularly—often monthly in severe cholestasis—because needs change with growth and bile flow. Binasss

10) Why MCT?
MCTs absorb without bile, helping calories stick and growth improve. Balance with essential fatty acids. NASPGHAN

11) How do we treat kidney acidosis?
Give alkali (bicarbonate or citrate) in divided doses; sometimes add a thiazide and potassium. This protects bones and growth. AJKD+1

12) Are there experimental “stem-cell” drugs?
Not for ARC today. Focus is on supportive care and prevention of complications; research continues. PubMed

13) Can we prevent RSV hospitalization?
Yes—eligible infants can receive nirsevimab once per season, or palivizumab monthly if indicated, per AAP/CDC guidance. CDC+1

14) Why does my child itch even when bile numbers improve?
Pruritus in cholestasis is complex; multiple mediators are involved. Stepwise therapy and skin care are usually needed. AASLD

15) Who should coordinate care?
A pediatric hepatologist and nephrologist, with dietitian, hematologist, dermatologist, PT/OT, and a primary pediatrician—plus a genetics counselor. Orpha

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.